Intellectual property rights in bioprinted organs

Introduction

Bioprinted organs are biological structures produced through advanced three-dimensional (3D) printing technologies using living cells, biomaterials, bioinks and supporting structures. These technologies aim to develop tissues and potentially functional organs for transplantation, medical research and drug testing.

Bioprinting combines biotechnology, engineering, medicine and computer science. Consequently, it creates complex intellectual property rights (IPR) issues concerning ownership of biological materials, printing methods, genetic information, computer-generated designs and the final bioprinted products.

In India, these issues are primarily governed by the Patents Act, 1970, the Copyright Act, 1957, the Designs Act, 2000 and relevant biological and medical regulations.

Patent protection for bioprinting technologies

Patents are among the most important forms of protection for bioprinting inventions. Researchers and companies may seek patents for novel bioinks, printing equipment, scaffold structures, cell-placement techniques and manufacturing processes.

Under Section 2(1)(j) of the Patents Act, 1970, an invention must involve novelty, an inventive step and industrial applicability. Therefore, a bioprinting invention must demonstrate a genuine technical contribution rather than merely applying an existing biological process.

However, certain statutory exclusions are particularly relevant:

Section 3(c): Excludes the mere discovery of a living thing or non-living substance occurring in nature.

Section 3(d): Restricts patents for certain new forms of known substances unless the statutory requirements are satisfied.

Section 3(i): Excludes methods of medicinal, surgical, curative, prophylactic, diagnostic or therapeutic treatment of humans or animals.

Section 3(j): Excludes plants and animals, in whole or in part, other than microorganisms, as well as essentially biological processes for their production or propagation.

A novel bioink composition or specialised bioprinter may potentially qualify for patent protection. However, a claim directed to a surgical method of implanting a bioprinted organ may fall within Section 3(i).

Ownership of biological materials and bioprinted organs

One major legal difficulty concerns ownership of the biological materials used in bioprinting. These may include stem cells, donor cells, genetically modified cells and tissue samples.

The legal position becomes complicated when cells are collected from human donors and subsequently modified or incorporated into a bioprinted structure.

Consent to collect or use biological material does not automatically settle every intellectual property question. The rights of researchers, institutions, donors and commercial developers must be examined separately.

In India, the Indian Council of Medical Research's National Ethical Guidelines for Biomedical and Health Research involving Human Participants provide important ethical standards for research involving human biological materials.

Additionally, the Transplantation of Human Organs and Tissues Act, 1994 regulates certain activities involving human organs and tissues. Its applicability to particular bioprinted products depends on their legal classification and intended use.

Copyright protection for digital organ designs

Bioprinting frequently depends on digital files containing three-dimensional anatomical models, tissue arrangements and printing instructions.

The Copyright Act, 1957 may protect original digital drawings, software, technical illustrations and other qualifying creative works.

Section 13 recognises copyright in specified categories of original works, including artistic and literary works. Section 14 identifies the exclusive rights available to copyright owners.

However, copyright does not automatically protect the underlying scientific idea, biological function or technical principle represented by a digital organ model. Patent law may be relevant where the model forms part of a patentable technical invention.

Protection of trade secrets and confidential research

Bioprinting companies may rely on trade secrets to protect confidential information that is difficult to patent or commercially sensitive.

Examples include:

Specialised bioink formulations.

Cell-culturing techniques.

Printing temperatures and environmental conditions.

Proprietary tissue-development protocols.

Manufacturing and quality-control processes.

Confidentiality agreements, employment contracts and research collaboration agreements can help protect such information.

Important judicial decisions

There are no widely recognised Indian Supreme Court decisions directly deciding intellectual property ownership of fully bioprinted human organs. However, several decisions provide relevant legal principles by analogy.

1. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court examined patentability under Section 3(d) of the Patents Act. It emphasised that modifications of known substances must satisfy the statutory requirements for patent protection.

This decision is relevant to bioprinting because companies may attempt to patent modified biological materials, bioinks or compositions derived from existing substances. Such inventions must satisfy the applicable patentability requirements.

2. Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979) 2 SCC 511

The Supreme Court explained the importance of novelty and inventive step in patent law.

The judgment is relevant to bioprinting technologies because merely combining known printing equipment and biological materials may not establish an inventive step. The invention must demonstrate a sufficient technical contribution.

3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381

The dispute concerned genetically modified seeds and the relationship between patent law and biological inventions.

Although it did not concern bioprinted organs, the judgment illustrates the legal difficulties associated with patent protection involving biological materials and genetically modified technologies.

4. Eastern Book Company v. D.B. Modak (2008) 1 SCC 1

The Supreme Court discussed the originality requirement for copyright protection and recognised the importance of a minimum degree of creativity.

This principle is relevant to original digital anatomical models, illustrations and software-related creative material used in bioprinting.

International legal framework

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes international minimum standards for patent protection. Article 27 addresses patentable subject matter and permitted exclusions.

The Convention on Biological Diversity and the Nagoya Protocol are also relevant where bioprinting research uses biological resources obtained from regulated sources. They promote conservation, sustainable utilisation and fair benefit-sharing.

However, these instruments do not independently establish ownership rights over every bioprinted organ.

Challenges and emerging legal concerns

The development of bioprinted organs creates several unresolved legal issues:

Ownership disputes: Researchers, hospitals and commercial companies may claim rights over different stages of development.

Donor consent: Questions may arise concerning the use of donated cells for commercial research.

Patent exclusions: Biological discoveries and certain treatment methods may fall outside patent protection.

Digital copying: Anatomical designs and printing files may be copied or commercially exploited without permission.

Access and affordability: Strong patent protection may affect the availability and cost of advanced regenerative treatments.

Conclusion

Intellectual property rights in bioprinted organs involve a combination of patent protection, copyright, trade secrets, contractual rights and biological-resource regulation. Indian patent law provides protection for qualifying technological inventions but excludes certain biological discoveries and treatment methods. Judicial decisions such as Novartis AG v. Union of India and Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries provide important principles for assessing patentability. A balanced legal framework must encourage technological innovation while protecting donor interests, ethical standards and equitable access to regenerative medical technologies.